DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,665 | +2.8% | 34,926 | -0.5% | 0.67% | +14.2% |
| Q2 2023 | $8,426 | -5.5% | 35,107 | -0.8% | 0.58% | -13.0% |
| Q1 2023 | $8,921 | -4.7% | 35,395 | +0.3% | 0.67% | +0.3% |
| Q4 2022 | $9,362 | -99.9% | 35,274 | -2.4% | 0.67% | -12.0% |
| Q3 2022 | $9,331,000 | +0.6% | 36,125 | -1.3% | 0.76% | +2.2% |
| Q2 2022 | $9,276,000 | -14.0% | 36,588 | -0.5% | 0.74% | -3.0% |
| Q1 2022 | $10,790,000 | -10.7% | 36,785 | +0.1% | 0.77% | -2.5% |
| Q4 2021 | $12,089,000 | +5.0% | 36,743 | -2.8% | 0.79% | +1.9% |
| Q3 2021 | $11,513,000 | +11.1% | 37,816 | -2.1% | 0.77% | +16.6% |
| Q2 2021 | $10,367,000 | +17.3% | 38,631 | -1.6% | 0.66% | +13.0% |
| Q1 2021 | $8,841,000 | -1.6% | 39,279 | -2.9% | 0.59% | -5.8% |
| Q4 2020 | $8,982,000 | -12.8% | 40,433 | -15.5% | 0.62% | -11.5% |
| Q3 2020 | $10,303,000 | -6.3% | 47,846 | -23.1% | 0.70% | -7.4% |
| Q2 2020 | $10,999,000 | +23.2% | 62,200 | -3.6% | 0.76% | +11.1% |
| Q1 2020 | $8,930,000 | -16.0% | 64,519 | -6.8% | 0.68% | +19.0% |
| Q4 2019 | $10,630,000 | +4.0% | 69,257 | -2.1% | 0.57% | +0.7% |
| Q3 2019 | $10,218,000 | -4.9% | 70,747 | -5.9% | 0.57% | -2.2% |
| Q2 2019 | $10,741,000 | +2.1% | 75,156 | -5.7% | 0.58% | +6.2% |
| Q1 2019 | $10,524,000 | -5.3% | 79,716 | -26.0% | 0.55% | -8.3% |
| Q4 2018 | $11,111,000 | -31.6% | 107,746 | -27.9% | 0.60% | -15.0% |
| Q3 2018 | $16,234,000 | +4.3% | 149,405 | -5.3% | 0.70% | +2.6% |
| Q2 2018 | $15,572,000 | -2.8% | 157,798 | -3.6% | 0.69% | -1.6% |
| Q1 2018 | $16,025,000 | +3.4% | 163,674 | -1.9% | 0.70% | +5.6% |
| Q4 2017 | $15,492,000 | +5.6% | 166,905 | -2.4% | 0.66% | +4.6% |
| Q3 2017 | $14,665,000 | -2.3% | 170,970 | -3.9% | 0.63% | -10.9% |
| Q2 2017 | $15,016,000 | -4.6% | 177,941 | -3.3% | 0.71% | -2.5% |
| Q1 2017 | $15,732,000 | +7.0% | 183,944 | -2.6% | 0.73% | +7.7% |
| Q4 2016 | $14,704,000 | -4.5% | 188,908 | -3.8% | 0.68% | -2.9% |
| Q3 2016 | $15,396,000 | -28.4% | 196,412 | -7.8% | 0.70% | -38.9% |
| Q2 2016 | $21,504,000 | +5.3% | 212,919 | -1.1% | 1.14% | +3.4% |
| Q1 2016 | $20,429,000 | +2.0% | 215,366 | -0.1% | 1.10% | +24.7% |
| Q4 2015 | $20,021,000 | +9.9% | 215,562 | +0.8% | 0.88% | +6.7% |
| Q3 2015 | $18,225,000 | +2.8% | 213,883 | +3.2% | 0.83% | +41250.0% |
| Q2 2015 | $17,734,000 | +2.4% | 207,199 | +1.6% | 0.00% | -99.7% |
| Q1 2015 | $17,313,000 | +0.8% | 203,916 | +1.8% | 0.58% | -41.5% |
| Q4 2014 | $17,175,000 | +19.3% | 200,380 | +5.8% | 0.99% | +13.8% |
| Q3 2014 | $14,391,000 | -1.6% | 189,403 | +2.0% | 0.87% | -1.7% |
| Q2 2014 | $14,618,000 | +10.7% | 185,675 | +5.5% | 0.88% | +0.6% |
| Q1 2014 | $13,203,000 | +9.6% | 176,041 | +12.9% | 0.88% | -1.3% |
| Q4 2013 | $12,042,000 | +17.4% | 155,981 | +5.4% | 0.89% | +5.9% |
| Q3 2013 | $10,260,000 | +13.3% | 148,016 | +3.5% | 0.84% | -5.6% |
| Q2 2013 | $9,057,000 | – | 143,078 | – | 0.89% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |